The VA is conducting market research for a prospective contractor to supply unit-dose, patient-specific low-energy radiopharmaceuticals (non-FDG F-18 agents) for routine and emergent diagnostic nuclear medicine and limited therapeutic procedures at the VA Northeast Ohio Healthcare System in Cleveland, OH, and the VA Kent Imaging and Infusion Center in Kent, OH. The contractor must hold current NRC/Agreement State, FDA, DOT, and other required authorizations to receive, possess, compound, transport, distribute, and dispose of radioactive materials, and doses must be prepared by or under a certified Nuclear Pharmacist in compliance with USP <797>/<825> and applicable regulations. Emergent orders must be delivered to both sites within 120 minutes of receipt, and the contractor must also support routine orders and Tc-99m tagged WBC processing. Anticipated performance is a base period from 01/01/2027 through 12/31/2027, plus four 12-month option years through 12/31/2031. Interested firms must show ability to provide all listed items and provide manufacturer authorization, business size/socioeconomic status, SAM UEI, licensure confirmation, and affirmative delivery capability; this is market research only, not a solicitation.